Scarica l'app Stockscreener
3.05
0.49%
-0.015
Dopo l'orario di chiusura:
3.22
0.17
+5.57%
Precedente Chiudi:
$3.065
Aprire:
$3.05
Volume 24 ore:
21,816
Relative Volume:
0.33
Capitalizzazione di mercato:
$26.54M
Reddito:
-
Utile/perdita netta:
$-6.01M
Rapporto P/E:
-2.4754
EPS:
-1.2321
Flusso di cassa netto:
$-5.71M
1 W Prestazione:
+2.87%
1M Prestazione:
+4.10%
6M Prestazione:
-43.20%
1 anno Prestazione:
+150.00%
Intervallo 1D:
$2.94
$3.22
Intervallo di 1 settimana:
$2.8716
$3.24
Portata 52W:
$0.64
$6.26
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Nome
Lixte Biotechnology Holdings Inc
Settore
Industria
Telefono
310 203 2902
Indirizzo
433 PLAZA REAL, BOCA RATON
Compare LIXT vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
3.05 | 26.54M | 0 | -6.01M | -5.71M | -1.2321 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lixte Biotechnology Holdings Inc Borsa (LIXT) Ultime notizie
Investor Mood: Is Lixte Biotechnology Holdings Inc stock forming a triangle pattern2026 Snapshot & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI
Lixte Biotechnology Holdings, Inc. (LIXTW) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year - newmediawire.com
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year - Financial-News.co.uk
LIXTE Biotechnology’s LB-100 May Transform Cancer Treatment—Yet Time Remains the Deciding Factor - bitget.com
LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes - NewMediaWire
LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes - TipRanks
LIXTE Biotechnology Reports Transformational Year with Clinical Progress and Strategic Expansion - citybuzz -
LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials - TipRanks
Lixte Biotech Receives Going Concern Alert Amid Insider and Institutional Sell-Offs—Who Will Fund the Recovery? - Bitget
LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials - newmediawire.com
LIXTE Biotechnology's LB-100 Emerges as Sole Clinical-Stage PP2A Inhibitor in Cancer Treatment Development - citybuzz -
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year - finance.yahoo.com
LIXTE Biotechnology’s Expanded Trial Could Be Its Best Shot at Breaking the Stagnation - Bitget
Lixte Biotechnology Holdings 10-K: $0 Revenue, $(1.26) EPS - TradingView
Lixte Biotechnology (NASDAQ: LIXT) posts larger loss and flags going-concern risk - Stock Titan
LIXTE Biotechnology Expands Clinical Trials for LB-100 in Challenging Ovarian and Colon Cancers - citybuzz -
Quarterly Earnings: Is Lixte Biotechnology Holdings Inc attractive for institutional investorsWeekly Trade Report & Daily Profit Focused Screening - baoquankhu1.vn
Lixte Biotechnology Stock: Precision Oncology Pioneer with High-Risk Development Pipeline for North - AD HOC NEWS
Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership - Benzinga
De La Soul Set to Lead Good Health Summit at Morehouse College - EBONY Magazine
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming - The Globe and Mail
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming - NewMediaWire
Treasury Yields: Can Lixte Biotechnology Holdings Inc Equity Warrant sustain its profitabilityEarnings Growth Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Pharma News: Whats the profit margin of Lixte Biotechnology Holdings IncStock Surge & Safe Capital Growth Trade Ideas - baoquankhu1.vn
LIXTE Biotechnology (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - The Globe and Mail
LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - NewMediaWire
Market Fear: Can Lixte Biotechnology Holdings Inc. Equity Warrant be recession proofFed Meeting & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Lixte Biotechnology Raises CEO Compensation Amid Leadership Support - TipRanks
Lixte (NASDAQ: LIXT) lifts CEO Geordan Pursglove base salary to $360k - Stock Titan
Lixte Biotechnology boosts CEO Geordan Pursglove's base salary to $360,000 - TradingView
Lixte Biotechnology stock faces scrutiny amid stalled pipeline progress and biotech sector volatilit - AD HOC NEWS
LIXTE Biotechnology Advances PP2A Inhibition Strategy to Enhance Cancer Treatment Combinations - citybuzz -
Lixte Biotechnology shares slide following purchase of UK-based Liora - MSN
Guidance Update: Is Lixte Biotechnology Holdings Inc a stock for growth or value investorsWeekly Gains Summary & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Breakout Move: Can Lixte Biotechnology Holdings Inc Equity Warrant be recession proofWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
Lixte Biotechnology Stock (ISIN: US53833K1060) Faces Short-Term Pressure Amid Strong Rising Trend an - AD HOC NEWS
Bond Watch: Does Lixte Biotechnology Holdings Inc align with a passive investing strategyOil Prices & Daily Stock Trend Watchlist - baoquankhu1.vn
LIXTE Biotechnology and Liora Technologies Partner to Advance Combined Cancer Treatment Approach - citybuzz -
Aug PostEarnings: Can Lixte Biotechnology Holdings Inc Equity Warrant be recession proof2026 Intraday Action & Stock Portfolio Risk Control - baoquankhu1.vn
Lixte Biotechnology Stock (ISIN: US53833K1060) Trades Steadily Amid Clinical-Stage Oncology Focus - AD HOC NEWS
Is Lixte Biotechnology Holdings Inc stock technically oversold2026 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
LIXTE Biotechnology Expands Ovarian Cancer Trial Through MD Anderson and GSK Partnership - citybuzz -
Lixte Amends Share Exchange, Clarifies Liora Ownership Structure - The Globe and Mail
Lixte Biotechnology Enters Amended Share Exchange to Consolidate Liora Ownership With Orbit Capital - TradingView
Lixte (NASDAQ: LIXT) restates Liora share exchange and Orbit’s 20% stake - Stock Titan
LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to Pipeline - Yahoo Finance
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline - TipRanks
Lixte Biotechnology Holdings Inc Azioni (LIXT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):